Advertisement
U.S. markets close in 3 hours 49 minutes
  • S&P 500

    5,252.87
    +4.38 (+0.08%)
     
  • Dow 30

    39,786.93
    +26.85 (+0.07%)
     
  • Nasdaq

    16,391.12
    -8.40 (-0.05%)
     
  • Russell 2000

    2,135.31
    +20.96 (+0.99%)
     
  • Crude Oil

    82.59
    +1.24 (+1.52%)
     
  • Gold

    2,236.10
    +23.40 (+1.06%)
     
  • Silver

    24.91
    +0.15 (+0.62%)
     
  • EUR/USD

    1.0797
    -0.0033 (-0.30%)
     
  • 10-Yr Bond

    4.1850
    -0.0110 (-0.26%)
     
  • GBP/USD

    1.2628
    -0.0010 (-0.08%)
     
  • USD/JPY

    151.3530
    +0.1070 (+0.07%)
     
  • Bitcoin USD

    70,897.46
    +1,774.51 (+2.57%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,962.49
    +30.51 (+0.38%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

Celldex announces issuance of patent for CD27 agonists

Celldex Therapeutics announced that the United States Patent and Trademark Office has issued US Patent No: 8,481,029 entitled "Human immune therapies using a CD27 agonist alone or in combination with other immune modulators" which broadly supports the company's product candidate CDX-1127. CD27, a signaling molecule expressed on T lymphocytes, can be effectively manipulated with activating antibodies to induce potent anti-tumor responses and, due to the restricted expression and regulation of CD27, may result in less toxicity—overcoming a key barrier that other targets in this class have faced. CDX-1127 is a fully human monoclonal antibody that targets CD27 and is currently in Phase 1 clinical development for the treatment of solid tumors and hematologic malignancies.

Advertisement